ICAM1 and COVID-19: Additionally, the anti-CHOL/COVID-19 effect of VA was controlled by 3 core genes, including ICAM1, NOS2, and CAT, suggesting the possible therapeutic and immunotherapeutic targets for treating COVID-19 or CHOL/ COVID-19.